文献速递免疫规划传染病防控与疫情报告

巴西引入PCV10后肺炎链球菌耐药动态:2007-2019年全国监测

Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019.
PubMed 文献 · Vaccine · 2021-03-09

巴西2010年将10价肺炎球菌结合疫苗(PCV10)纳入免疫规划,本研究基于全国侵袭性肺炎球菌病监测系统,分析PCV10引入前后肺炎链球菌(Spn)对抗菌药物的敏感性。共纳入11,380株分离株,结果显示PCV10引入后三年内青霉素和头孢曲松非敏感率下降,但2013年后再次上升,2019年分别达39.4%和19.7%,且非疫苗血清型19A、6C和23A与耐药相关。

要点

  • PCV10引入后三年内青霉素和头孢曲松非敏感率下降,但2013年后回升。
  • 2017-2019年<5岁儿童脑膜炎患者中青霉素非敏感率53.9%,头孢曲松28.0%。
  • 耐药与PCV10非疫苗血清型19A、6C和23A相关。

核心结论

  • PCV10引入后三年内抗菌药物非敏感Spn减少,但随后增加并与非PCV10血清型相关。
  • 抗菌药物敏感性监测对指导抗生素治疗政策至关重要。

研究设计与样本

  • 基于全国侵袭性肺炎球菌病监测系统的监测研究,共纳入11,380株Spn分离株。
  • 以PCV10引入前(2007-2009年)为参考,按每三年时段评估抗菌药物敏感性率。

主要发现

  • PCV10引入后三年(2011-2013年)青霉素MIC≥0.125 mg/L的比例从28.1%降至22.5%,头孢曲松MIC≥1.0 mg/L的比例从11.3%降至7.6%。
  • 2019年青霉素和头孢曲松MIC≥相应阈值的Spn比例分别增至39.4%和19.7%。
  • 2017-2019年<5岁儿童脑膜炎患者中青霉素非敏感率53.9%,头孢曲松非敏感率28.0%。
  • 2017-2019年多重耐药率达25%。
  • 血清型19A、6C和23A与抗菌药物非敏感最相关。

关键数值与推荐

  • 抗菌药物非敏感定义为中介或耐药。
  • 青霉素非敏感阈值MIC≥0.125 mg/L,头孢曲松非敏感阈值MIC≥1.0 mg/L。

临床怎么用

  • 应持续监测肺炎链球菌抗菌药物敏感性以指导抗生素治疗政策。
  • 临床应关注非PCV10血清型(如19A、6C、23A)引起的耐药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brazil introduced 10-valent pneumococcal conjugate vaccine (PCV10) into its immunization program in 2010. We assessed antimicrobial susceptibility of Streptococcus pneumoniae (Spn) obtained from a national surveillance system for invasive pneumococcal diseases (IPD) before/after PCV10 introduction. METHODS: Antimicrobial non-susceptible isolates were defined as intermediate or resistant. Minimum inhibitory concentrations (MICs) to penicillin and ceftriaxone were analyzed by year. Antimicrobial susceptibility rates were assessed for each three-year-period using the pre-PCV10-period as reference. Susceptibility of vaccine-types was evaluated for 2017-2019. RESULTS: 11,380 isolates were studied. Spn with penicillin ≥ 0.125 mg/L and ceftriaxone ≥ 1.0 mg/L decreased in the three-years after PCV10 introduction (2011-2013: penicillin, 28.1-22.5%; ceftriaxone, 11.3%-7.6%) versus pre-PCV10-years (2007-2009: penicillin, 33.8-38.1%; ceftriaxone, 17.2%-15.6%). After 2013, the proportion of Spn with those MICs to penicillin and ceftriaxone increased to 39.4% and 19.7% in 2019, respectively. Non-susceptibility to penicillin and ceftriaxone increased in 2014-2016, and again in 2017-2019 especially among children < 5 years with meningitis (penicillin, 53.9%; ceftriaxone, 28.0%); multidrug-resistance reached 25% in 2017-2019. Serotypes 19A, 6C and 23A were most associated with antimicrobial non-susceptibility. CONCLUSIONS: Antimicrobial non-susceptible Spn decreased in the three-years after vaccination but subsequently increased and was associated with non-PCV10-types. Antimicrobial susceptibility surveillance is fundamental for guiding antibiotic therapy policies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Brandileone MC, Almeida SCG, Bokermann S, et al. Dynamics of antimicrobial resistance of Streptococcus pneumoniae following PCV10 introduction in Brazil: Nationwide surveillance from 2007 to 2019. Vaccine. 2021. PMID: 33707062. doi:10.1016/j.vaccine.2021.02.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。